GLP-1受体激动剂与终末期肾病患者住院及死亡风险
该匹配回顾性队列研究利用某透析机构电子健康记录,纳入2018年1月至2024年4月起始每周三次中心血透的成人ESKD患者,其中透析起始后30天内使用GLP-1 RA者2492例,按1:1匹配未使用者。结果显示GLP-1 RA独立关联住院率降低9%、死亡率降低17%。
要点
- 在起始中心血透的ESKD患者中,GLP-1 RA使用与住院率降低9%独立相关
- GLP-1 RA使用与死亡率降低17%独立相关
- 该研究为回顾性队列,尚需随机试验验证ESKD人群中的疗效
核心结论
- 在起始中心血透的ESKD患者中,GLP-1 RA使用独立关联住院率降低9%和死亡率降低17%。
研究设计与样本
- 匹配回顾性队列研究,使用某肾脏护理机构电子健康记录,纳入2018年1月至2024年4月起始每周三次中心血透的成人ESKD患者。
- 透析起始后30天内使用GLP-1 RA者2492例,按1:1匹配未使用者;随访至死亡或研究结束(2024年7月31日)。
主要发现
- GLP-1 RA使用者平均年龄63±12岁,男性占59%,98%有糖尿病诊断(对照73%),76%有透析前肾脏科照护(对照67%),白人占46%(对照39%),平均BMI 33±8 kg/m²(对照30±8)。
- 匹配调整后,GLP-1 RA与住院率降低独立相关,发生率比为0.91(95%CI 0.87至0.96)。
- 匹配调整后,GLP-1 RA与死亡率降低独立相关,发生率比为0.83(95%CI 0.73至0.95)。
临床怎么用
- 对于起始中心血透的糖尿病ESKD患者,继续使用GLP-1 RA可能与较低住院和死亡风险相关,但需结合个体情况谨慎决策。
局限性
- 为回顾性队列研究,非随机对照试验,存在残余混杂可能;原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Glucagon-like peptide-1 receptor agonist have shown clinical benefits in patients with chronic kidney disease, but there are no randomized trials to support their efficacy in ESKD. This matched retrospective cohort study used electronic health record from a dialysis provider and was conducted in diabetic, incident in-center hemodialysis patients. Results indicated that continued use of glucagon-like peptide-1 receptor agonist is associated with a 9% lower hospitalization and a 17% lower mortality rate. BACKGROUND: The recent clinical trial FLOW showed that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), reduced the risk of clinical outcomes and death from cardiovascular causes in patients with CKD and type 2 diabetes. Given the substantial benefit to patients with CKD, the question remains whether these drugs benefit patients with ESKD. We sought to evaluate the impact of GLP-1 RA use in patients with incident ESKD on clinical outcomes. METHODS: Patients included in this matched retrospective cohort study were adult patients with ESKD who initiated thrice-weekly in-center hemodialysis at a kidney care organization between January 2018 and April 2024. Using internal electronic health record data, eligible patients who initiated dialysis on a GLP-1 RA (with evidence of a GLP-1 RA prescription in the first 30 days after dialysis initiation; n =2492) were matched 1:1 to those not on a prescription. Patients were followed from index date until death or the end of the study (July 31, 2024). Incident rate ratios were estimated using a negative binomial distribution with a random intercept to account for the matched nature of the data. RESULTS: Patients with a GLP-1 RA prescription in the first month of dialysis had a mean±SD age of 63±12 years and were predominately male (59%). Compared with other eligible dialysis patients, nearly all patients on a GLP-1 RA had a known diagnosis of diabetes (98% versus 73%), a majority had evidence of predialysis nephrology care (76% versus 67%), were of White race (46% versus 39%), and had a mean±SD body mass index of 33±8 kg/m 2 (versus 30±8). After matching and adjustment, GLP-1 RAs were independently associated with lower hospitalization (incidence rate ratios, 0.91 [0.87 to 0.96]) and mortality (Incidence rate ratios, 0.83 [0.73 to 0.95]) rates. CONCLUSIONS: Among incident in-center hemodialysis patients, GLP-1 RA use was independently associated with a 9% lower hospitalization rate and a 17% lower mortality rate.
引用
- Karpinski S, Qazi R, Bjordahl T, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with ESKD. Clin J Am Soc Nephrol. 2026. PMID: 42640716. doi:10.2215/CJN.0000001208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。